Active Clinical Studies

Protocol Title: SunRISe - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

Principal Investigator: David Lieber, MD

Indication: High-Risk Non-Muscle Invasive Bladder Cancer

Study Description: The purpose of this study is to compare the effects (both good and bad) of the investigational drug delivery system (TAR-200) in combination with cetrelimab or TAR-200 alone to the effects of study drug comparator intravesical (medicine that is put directly into the bladder instead of being taken like a pill or put into veins) BCG in patients with HR-NMIBC.

Protocol Title: AVANZAR - A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations

Principal Investigator: Mohammed Memon, MD

Indication: Advance or Metastatic Lung Cancer

Study Description: We are doing this study to learn more about whether an investigational drug called datopotamab deruxtecan (also called Dato-DXd) given in combination with two approved medicines (called durvalumab and carboplatin) will work and be tolerable for the treatment of locally advanced or metastatic NSCLC. This combination is investigational. In this study, we will be comparing the experimental treatment with an approved treatment called pembrolizumab, which will be given in combination with platinum-based chemotherapy. This study will also help us to better understand the studied disease and associated health problems.

Protocol Title: Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer

Principal Investigator: Mohammad Memon, MD

Indication: Locally Advanced (inoperable) or metastatic HR+/HER2- breast cancer 

Study Description: The purpose of this study is to learn more about treatment with an experimental drug called capivasertib, added to a standard of care treatment fulvestrant + CDK4/6i (palbociclib or ribociclib) for patients with advanced breast cancer and to better understand the studied disease and associated health problems.
 

Protocol Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Principal Investigator: Ahmed Jouan, MD

Indication: Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Study Description: The purpose of this study is to see if an experimental drug, called milvexian in addition to standard of care, is safe and useful in reducing the risk of future ischemic stroke in subjects after ischemic stroke or transient ischemic attack compared to placebo (tablet with no active drug) in addition to standard of care. An experimental drug is one that is not approved by the United States Food and Drug Administration (FDA).